Showing 5851-5860 of 9511 results for "".
- Allergan Rolls Out "Not Cool vs. Cool"CoolSculpting Campaign Starring Professional Male Athlete Brand Ambassadorshttps://practicaldermatology.com/news/allergan-rolls-out-not-cool-vs-coolcoolsculpting-campaign-starring-professional-male-athlete-brand-ambassadors/2457905/Allergan’s new "Not Cool vs. Cool" Multi-Channel Campaign for CoolSculpting® stars Professional Athlete Brand Ambassadors: Figure Skater Johnny Weir and Go
- Apple Update Brings Healthcare Records to Phoneshttps://practicaldermatology.com/news/apple-update-brings-healthcare-records-to-phones/2457906/Apple has introduced a significant update to the Health app with the iOS 11.3 beta introducing a feature that gives customers access to their medical records on their iPhone. The updated H
- Amazon, Berkshire Hathaway, JPMorgan Chase Partner on Healthcarehttps://practicaldermatology.com/news/amazon-berkshire-hathaway-jpmorgan-chase-partner-on-healthcare/2457907/Amazon, Berkshire Hathaway, and JPMorgan Chase & Co. are partnering in an effort to seek solutions for delivering healthcare to their employees. The three companies will pursue this objective through an independent company that is free from profit-making incentives and constraints, they said
- Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in EBhttps://practicaldermatology.com/news/abeona-receives-fda-regenerative-medicine-advanced-therapy-designation-for-eb-101-gene-therapy-in-eb/2457908/The US Food and Drug Administration (FDA) granted the Regenerative Medicine Advanced Therapy (RMAT) designation to EB-101, Abeona Therapeutics Inc.’s gene-corrected autologous cell therapy product for patients with recessive dystrophic epidermolysis bullosa (RDEB). “EB-101 is
- Alastin Skincare Launches Restorative Neck Complexhttps://practicaldermatology.com/news/alastin-skincare-launches-restorative-neck-complex/2457916/Alastin Skincare, Inc. has incorporated its proven, proprietary TriHex Technology into a new product designed for the specific needs of the neck and décolletage: Restorative Neck Complexwith TriHex Technology. This breakthrough treatment is formulated to addr
- Anti-IL22 Therapy May Represent New Treatment Option for Severe ADhttps://practicaldermatology.com/news/researchers-close-in-on-possible-new-treatment-for-severe-ad/2457913/New research suggests that IL-22/Th22 targeting may offer a novel treatment alternative for patients with severe atopic dermatitis (AD). The findings, which appear in the Journal of the American Academy of Dermatology, provide the first e
- Retin-A Micro Gel Microsphere 0.06% Now Available from Ortho Dermatologics to Treat Acnehttps://practicaldermatology.com/news/retin-a-micro-gel-microsphere-006-now-available-from-ortho-dermatologics-to-treat-acne/2457914/Retin-A Micro (tretinoin) gel microsphere 0.06% is now available commercially to healthcare professionals. The FDA approved Ortho Dermatologics' Supplemental New Drug Application (sNDA) for Retin-A Micro (tretinoin) gel microsphere 0.06% for topical application in the treatment of acne vulgar
- Research Elucidates LIGHT's Role in ADhttps://practicaldermatology.com/news/research-elucidates-lights-role-in-ad/2457919/LIGHT, a member of the tumor necrosis factor (TNF) super family, directly controls the hyperproliferation of keratinocytes as well as the expression of periostin, a protein that contributes to the clinical features of atopic dermatitis and other inflammatory skin diseases such as scleroderma, rep
- FDA Accepts Ortho Dermatologics' Filing for IDP-121 Acne Treatment In Lotion Formhttps://practicaldermatology.com/news/fda-accepts-ortho-dermatologics-filing-for-idp-121-acne-treatment-in-lotion-form/2457925/The FDA has accepted Ortho Dermatologics' New Drug Application for IDP-121 (tretinoin 0.05%) lotion (Altreno) with a PDUFA action date of Aug. 27, 2018. If approved, Altreno will be the first tretinoin product in lotion form rather than a gel or cream.
- Desmoplastic Melanoma May Be Highly Responsive to Anti-PD-1/PD-L1 Therapieshttps://practicaldermatology.com/news/desmoplastic-melanoma-may-be-highly-responsive-to-anti-pd-1pd-l1-therapies/2457926/Patients with desmoplastic melanoma are more responsive to immune-activating anti-PD-1/PD-L1 therapies than previously assumed, Moffitt Cancer Center researchers report in the Jan. 10 issue of Nature. Pembrolizumab and niv